For our Spotlight on biomarker discovery and development we carried out a survey to gain insights into biomarkers used, their challenges and future outlook.
Browsing: demyelinating disease
A team of researchers have utilized radiocarbon dating to determine that there is little regeneration of oligodendrocytes in the brains of people living with multiple sclerosis. However, the oligodendrocytes that survive the autoimmune attack can replenish lost myelin.
A new cellular immunotherapy that targets the Epsein–Barr virus could improve the symptoms and quality of life for individuals with multiple sclerosis.
In this interview, we spoke with Bruce Trapp about how his team identified a new subtype of multiple sclerosis, termed myelocortical multiple sclerosis.
Not able to attend ECTRIMS this year? You can catch up with all the action from today with our daily video, best of social media and poster highlights.
Today was the second day of ECTRIMS, with more fascinating talks and exciting posters. You can catch up on the highlights and headlines in our daily update.
Today was the first day of ECTRIMS 2018 and we’re excited to be attending! You can find a daily video update, photos from the day, poster highlights and more in our daily updates.
A team from Cleveland Clinic (OH, USA) has identified a new subtype of multiple sclerosis, termed myelocortical multiple sclerosis.
The US FDA has accepted for filing a resubmission of the New Drug Application for cladribine tablets by Merck; this could be a potential treatment for patients with relapsing forms of multiple sclerosis.
The second and final installment of our discussion focuses on the use of stem cells and what further research is on the horizons for multiple sclerosis.